MedPath

Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments

Phase 2
Completed
Conditions
Lymphoma, Non-Hodgkin
Registration Number
NCT00045877
Lead Sponsor
Chiron Corporation
Brief Summary

The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with low-grade Non-Hodgkin's Lymphoma who have previously failed Rituxan treatments.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (54)

University of Arkansas for Medical Sciences

🇺🇸

Little Rock, Arkansas, United States

Comprehensive Blood and Cancer Center

🇺🇸

Bakersfield, California, United States

California Oncology of the Central Valley

🇺🇸

Fresno, California, United States

Virginia K. Crosson Cancer Center

🇺🇸

Fullerton, California, United States

Pacific Shores Medical Group

🇺🇸

Los Alamitos, California, United States

Wilshire Oncology Medical Group

🇺🇸

West Covina, California, United States

California Cancer Care Inc.

🇺🇸

Greenbrae, California, United States

Santa Barbara Hematology Oncology Medical Group

🇺🇸

Solvang, California, United States

UCLS Medical Center

🇺🇸

Los Angeles, California, United States

Facey Medical Foundation

🇺🇸

Mission Hills, California, United States

Scroll for more (44 remaining)
University of Arkansas for Medical Sciences
🇺🇸Little Rock, Arkansas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.